UC researchers open Phase 2 clinical trial to test new combination treatment for glioblastomas

A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas (GBM), the most deadly form of brain tumors.

InvaGen recalls seizure treatment due to leaking sachets

Share this article The product is sold in foil pouches with each sachet containing a 500mg dose of Vigabatrin. Credit: PeopleImages.com – Yuri A /

December 11, 2023

Impact of CLK kinase inhibitors 1C8 and GPS167 on cancer cell proliferation and metastasis

A new research paper was published in Oncotarget’s Volume 15 on May 16, 2024, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and

May 21, 2024

Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling strong investor confidence in its cystic fibrosis (CF)

February 25, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.